Levodopa–induced dyskinesias in the absence of nigrostriatal degeneration
Funding agencies: Funding from Spanish Science and Education Ministry and European Union (REPLACES). Agence Nationale de la Recherche, MJFF, FP7 from EU, France Parkinson, Fondation de France, Cariplo Foundation.
Relevant conflicts of interest/financial disclosures: Dr. J.A. Obeso has served previously in the Advisory Board of GSK (UK), and received honorarium for lecturing in meetings organized by GSK (Spain), Lundbeck-TEVA and UCB. Dr. Bezard has equity stake in Motac holding Ltd and receives consultancy payments from Motac Neuroscience Ltd. Dr. C.W. Olanow received consulting fees from Novartis and Orion.
Full financial disclosures may be found in the Acknowledgments section online.
No abstract is available for this article.